Healthcare / BiotechnologyKOSDAQ
$2725.00
-175.00 (-6.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-8.3B · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$73.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-135.3%
↓Gross Margin
90.7%
↑Debt/Equity
0.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.0%
FCF CAGR
—
FCF margin
-7044.0%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $158.6M · net income $-16.04B · FCF $-11.17B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $158.6M | $158.6M | $370.7M | $294.1M | $179.5M |
| Net Income | $-16.04B | $-16.04B | $-10.14B | $-1.75B | $-6.72B |
| EBITDA | $-13.44B | $-13.44B | $-8.64B | $1.06B | $-3.73B |
| EPS | -597.00 | -597.00 | -378.00 | -66.00 | -254.00 |
| Gross Margin | 90.7% | 90.7% | 93.5% | 88.3% | 89.4% |
| Operating Margin | -8997.2% | -8997.2% | -2076.4% | -2182.5% | -3604.4% |
| Net Margin | -10115.3% | -10115.3% | -2735.2% | -594.8% | -3741.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.75 | 0.75 | 0.35 | 0.12 | 0.71 |
| Current Ratio | 1.82 | 1.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-11.17B | $-11.17B | $-8.33B | $-5.58B | $-5.64B |
| Returns | |||||
| ROE | -135.3% | -135.3% | -36.6% | -4.9% | -20.1% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 134.45 | — |
| P/B | 6.18 | 6.18 | 2.81 | 4.07 | 4.02 |
| Growth & Yield | |||||
| Revenue Growth | -57.2% | -57.2% | 26.0% | 63.9% | — |
| EPS Growth | -57.9% | -57.9% | -472.7% | 74.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-378.00 → -597.00
Residual
-11.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.